Benzinga | Sep 9, 2020 06:18AM EDT

JP Morgan Initiates Coverage On Horizon Therapeutics with Overweight Rating, Announces Price Target of $110

JP Morgan analyst Chris Schott initiates coverage on Horizon Therapeutics (NASDAQ:HZNP) with a Overweight rating and announces Price Target of $110.